This decision expands access to renal denervation to many more patients throughout the United States. Recor Medical and Medtronic both gained FDA approval for their RDN systems in 2023, and other vendors are actively developing their own treatment options.

Intellia Therapeutics paused clinical trials for ATTR-CM and ATTR-PN after a patient was hospitalized due to a significant liver injury. 

After President Donald Trump told reporters he underwent an MRI—adding that the results were “perfect”—it remains unclear why, exactly, the scan was ordered in the first place.

According to the FDA, the drugs are not dissolving correctly. This can impact their ability to lower a patient’s cholesterol as intended.

PARTNER 3 has been one of the most closely watched clinical trials in cardiology for many years now. Michael J. Mack, MD, presented a seven-year update during a packed session at TCT 2025. 

The Cardiovascular Research Foundation and Fogarty Innovation are joining forces to help innovative researchers and technologies flourish in today's competitive medtech industry. The two organizations made the partnership official at TCT 2025 in San Francisco. 

"PET has changed the practice of nuclear medicine in general and I think it is going to revitalize the practice of cardiology,"  Marcelo Di Carli, MD, told Cardiovascular Business. He noted that more practices seem interested in implementing PET than ever before.

When patients require PCI and TAVR, performing them at the same time is associated with both short- and long-term benefits. 

Different subtypes of depression are association with specific cardiometabolic diseases, according to new data out of the Netherlands. 

What do you get when you fall in love with AI in healthcare? A guy with a pin to burst your bubble. 

The court's ruling is backed by the American Medical Association, which submitted an amicus brief arguing that "scope creep" threatens patient safety.